High levels of anti-SARS-CoV-2 IgG antibodies in previously infected cancer patients after a single dose of BNT 162b2 vaccine

As patients with cancer constitute a vulnerable population at higher risk of contracting severe COVID-19, they represent a priority group for SARS-CoV-2 vaccination. However, despite favouring these patients theoretically, cancer patients were excluded from major registration trials on SARS-CoV-2 vaccines [1]. Furthermore, two recent reports on the immunogenicity of mRNA vaccines in cancer patients excluded those from the study having previous SARS-CoV-2 exposure [2,3]. We compared IgG antibody levels after one or two doses of BNT162b2 (Pfizer-BioNTech) vaccine in cancer patients with or without prior SARS-CoV-2 infection.

Lascia un commento